Posterior Reversible Leukoencephalopathy Syndrome in a patient after second dose of Rituximab for treatment of resistant Thrombotic Thrombocytopenic Purpura
Article Sidebar
Main Article Content
Article Details
Copyright (c) 2018 Asif S, et al.
This work is licensed under a Creative Commons Attribution 4.0 International License.
The Journal of Clinical Nephrology is committed in making it easier for people to share and build upon the work of others while maintaining consistency with the rules of copyright. In order to use the Open Access paradigm to the maximum extent in true terms as free of charge online access along with usage right, we grant usage rights through the use of specific Creative Commons license.
License: Copyright © 2017 - 2025 | 
Open Access by Journal of Clinical Nephrology is licensed under a Creative Commons Attribution 4.0 International License. Based on a work at Heighten Science Publications Inc.
With this license, the authors are allowed that after publishing with the journal, they can share their research by posting a free draft copy of their article to any repository or website.
Compliance 'CC BY' license helps in:
| Permission to read and download | ✓ |
| Permission to display in a repository | ✓ |
| Permission to translate | ✓ |
| Commercial uses of manuscript | ✓ |
'CC' stands for Creative Commons license. 'BY' symbolizes that users have provided attribution to the creator that the published manuscripts can be used or shared. This license allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author.
Please take in notification that Creative Commons user licenses are non-revocable. We recommend authors to check if their funding body requires a specific license.
Mondal S, Goswami RP, Sinha D, Basu K, Das S, et al. Posterior reversible encephalopathy syndrome in a patient with lupus nephritis on rituximab therapy: a challenge to find the offender. Lupus. 2015; 25: 445-446. Ref.: https://goo.gl/AWWGxH
Legriel S, Pico F, Azoulay E. Understanding Posterior Reversible Encephalopathy Syndrome. Annual Update in Intensive Care and Emergency Medicine. 2011; 1: 631-653. Ref.: https://goo.gl/JeGsDz
Siddiqi A. Rituximab as a possible cause of posterior reversible encephalopathy syndrome. Australas Med J. 2011; 4: 513-515. Ref.: https://goo.gl/B3ZA8x
Mehta Y, Ramachandran K, Gundre P, Kupfer Y, Tessler S. Posterior Reversible Encephalopathy Syndrome in a Patient with Newly Diagnosed Systemic Lupus Erythematosus and Thrombotic Thrombocytopenic Purpura. Chest. 2009; 136. Ref.: https://goo.gl/dLdrAA
Harirchian M, Ghaffarpour M, Tabaeizadeh M, Siroos B. Immunosuppressive Drugs, an Emerging Cause of Posterior Reversible Encephalopathy Syndrome: Case Series. J Stroke Cerebrovasc Dis. 2015; 24:191-195. Ref.: https://goo.gl/Y2YLRj
Mavragani CP, Vlachoyiannopoulos PG, Kosmas N, Boletis I, Tzioufas AG, et al. A case of reversible posterior leucoencephalopathy syndrome after rituximab infusion. Rheumatology. 2004; 43: 1450-1451. Ref.: https://goo.gl/zqEeZX
Vargas A, Zeidman LA. Posterior Reversible Encephalopathy Syndrome with Rituximab in Hodgkin’s Lymphoma and Idiopathic Thrombocytopenic Purpura. J Neurol Transl Neurosci. 2013; 1: 1023. Ref.: https://goo.gl/driFv1
Bhat S, Rahman S. Rituximab Treatment in New and Refractory Thrombotic Thrombocytopenic Purpura (TTP) Patients: A Review. Int J Med Res Prof. 2016; 2: 1-6. Ref.: https://goo.gl/B9NbpY
Scully M. Rituximab in the treatment of TTP. Hematology. 2012; 17: 22-24. Ref.: https://goo.gl/pQrHQa
Habli M, Elyoussef N, Khoury M, Joubran Fares N. Rituximab-related posterior reversible encephalopathy syndrome in HUS patient post kidney transplant. Int J Case Rep Images. 2016; 7: 135-139. Ref.: https://goo.gl/b26waz